Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Novel approaches in risk-based breast cancer screening

Isabel Rubio • 13 Mar 2025
BCC 2025
Breast Cancer

Isabel Rubio, MD, PhD, Clinica Universidad de Navarra, Madrid, Spain, explores the shift from age-based to risk-stratified breast cancer screening, integrating factors such as family history, polygenic risk scores, and mammographic breast density. Future implementation of risk-adapted screening could improve early detection and prevention strategies, tailoring screening intervals and interventions to individual risk profiles. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Isabel Rubio

Assessing the role of treatment de-escalation in early breast cancer
1:30
Assessing the role of treatment de-escalation in early breast cancer
Isabel Rubio • 13 Mar 2025
Novel guidelines on PET imaging for staging early breast cancer
0:59
Novel guidelines on PET imaging for staging early breast cancer
Isabel Rubio • 13 Mar 2025
Impact of whole-breast irradiation in low-risk older breast cancer
1:12
Impact of whole-breast irradiation in low-risk older breast cancer
Isabel Rubio • 13 Mar 2025
Promoting women in surgical leadership: insights from ESSO 43 on empowering female surgeons
1:22
Promoting women in surgical leadership: insights from ESSO 43 on empowering female surgeons
Isabel Rubio • 4 Oct 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals